These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 17821901)

  • 41. 60 years studying heart-disease risk.
    Levy D
    Nat Rev Drug Discov; 2008 Sep; 7(9):715. PubMed ID: 19172683
    [No Abstract]   [Full Text] [Related]  

  • 42. The reply.
    Boyden TF
    Am J Med; 2015 Oct; 128(10):e75. PubMed ID: 26387006
    [No Abstract]   [Full Text] [Related]  

  • 43. Profiling a landmark clinical trial: Scandinavian Simvastatin Survival Study.
    Guptha S
    Curr Opin Lipidol; 1995 Oct; 6(5):251-3. PubMed ID: 8520845
    [No Abstract]   [Full Text] [Related]  

  • 44. Medication for hypercholesterolemia and the risk of nonfatal acute myocardial infarction: case-control study in Japan.
    Circ J; 2002 May; 66(5):463-8. PubMed ID: 12030341
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [BECAIT [Bezafibrate Coronary Atherosclerosis Intervention Trial]].
    Yoshino G; Hirano T; Kazumi T
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():433-5. PubMed ID: 11347109
    [No Abstract]   [Full Text] [Related]  

  • 46. Lapaquistat acetate: development of a squalene synthase inhibitor for the treatment of hypercholesterolemia.
    Stein EA; Bays H; O'Brien D; Pedicano J; Piper E; Spezzi A
    Circulation; 2011 May; 123(18):1974-85. PubMed ID: 21518985
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Secondary prevention in stroke. Where's the evidence?
    Hepple PA
    BMJ; 2009 May; 338():b2095. PubMed ID: 19474011
    [No Abstract]   [Full Text] [Related]  

  • 48. Achieving optimal lipid goals in patients with coronary artery disease.
    Karalis DG; Subramanya RD; Hessen SE; Liu L; Victor MF
    Am J Cardiol; 2011 Mar; 107(6):886-90. PubMed ID: 21247526
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Should the treatment of diabetic dyslipidemia be modified after the Action to Control Cardiovascular Risk in Diabetes Lipid study?].
    Pérez A
    Endocrinol Nutr; 2010 Dec; 57(10):457-9. PubMed ID: 20688585
    [No Abstract]   [Full Text] [Related]  

  • 50. [Treatment of hypercholesteremia with cholestyramine].
    Jacotot B; Beaumont V; Buxtorf JC; Le Parco JC; Beaumont JL
    Therapeutique; 1972 Mar; 48(3):225-30. PubMed ID: 4560997
    [No Abstract]   [Full Text] [Related]  

  • 51. [Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study].
    Ai M; Yoshida M
    Nihon Rinsho; 2010 Nov; 68 Suppl 9():285-90. PubMed ID: 21661165
    [No Abstract]   [Full Text] [Related]  

  • 52. Rule set reduction using augmented decision table and semantic subsumption techniques: application to cholesterol guidelines.
    Shiffman RN; Greenes RA
    Proc Annu Symp Comput Appl Med Care; 1992; ():339-43. PubMed ID: 1482893
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical and economic impact of clinical pharmacy service on hyperlipidemic management in Hong Kong.
    Chung JS; Lee KK; Tomlinson B; Lee VW
    J Cardiovasc Pharmacol Ther; 2011 Mar; 16(1):43-52. PubMed ID: 20924095
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Regression of coronary atherosclerosis: is it possible?
    Shepherd J; Packard CJ
    Br Heart J; 1988 Feb; 59(2):149-50. PubMed ID: 3342156
    [No Abstract]   [Full Text] [Related]  

  • 55. Eligibility for lipid-lowering drug therapy in primary prevention: how do the Adult Treatment Panel II and Adult Treatment Panel III Guidelines compare?
    Gotto AM; Kuller LH
    Circulation; 2002 Jan; 105(2):136-9. PubMed ID: 11790688
    [No Abstract]   [Full Text] [Related]  

  • 56. Getting lost among the guidelines: the difference between patient-focused treatment and population management.
    Weinrauch LA; Barkoudah E
    Am J Med; 2015 Oct; 128(10):e73. PubMed ID: 26387005
    [No Abstract]   [Full Text] [Related]  

  • 57. [Anti-hyperlipidemic agents].
    Kinoshita M
    Nihon Rinsho; 2002 May; 60(5):968-74. PubMed ID: 12030001
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [What has changed in therapy of vascular patients (role of statins and beta-adrenoblockers)].
    Pokrovskiĭ AV; Goloviuk AL
    Angiol Sosud Khir; 2010; 16(2):7-11. PubMed ID: 21032867
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Guggulipid supplements for high cholesterol questionable.
    Mayo Clin Health Lett; 2004 Jun; 22(6):4. PubMed ID: 15199914
    [No Abstract]   [Full Text] [Related]  

  • 60. [Hyperlipidemia].
    Wakatsuki A
    Nihon Rinsho; 2006 Apr; 64 Suppl 4():375-80. PubMed ID: 16689337
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.